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The relationship of vascular pathology with Alzheimer disease (AD) is well-established. The clinical expression of a moderate AD load is powerfully modulated by the presence of lacunar infarcts, 1 and midlife hypertension is a risk factor for the development of dementia. 2 On the other hand, Parkinson disease (PD) has been associated with toxins, mitochondrial dysfunction, and impaired degradation of misfolded or abnormally aggregated proteins, but not vascular problems. Until now. As is often the case before a major paradigm-shifting hypothesis is presented-on a grander scale, both relativity theory and the prion hypothesis come to mind-there had been vague rumblings pointing to alteration in the microvasculature in PD. We and others have documented bloodbrain barrier (BBB) changes in PD. 3, 4 In addition, there are reports of increased capillaries in the substantia nigra, 5 and greater severity of axial motor symptoms in association with white matter lesions (WML), 6 but the article by Janelidze et al. 7 in this issue of Neurology ® provides a novel perspective with regard to this area of investigation. These authors measured a number of markers of angiogenesis in the CSF in a group of patients with PD-both with and without dementia-and controls, and in 2 validation cohorts, one of them with neuropathologic confirmation of the diagnosis. The proteins investigated relate to the vascular endothelial growth factor (VEGF) family and their receptors, some of which increase, while others decrease, BBB permeability. The data are similar whether all patients with PD or the subgroups with and without dementia are considered, although the threshold for statistical significance is not surpassed in all comparisons. After correcting for age and sex, patients with PD have a distinctive pattern, with higher levels of markers or peptide/receptor ratios increasing BBB permeability, and lower levels of the one (Ang2) that reduces permeability. In patients with PD, these levels correlate with clinical measures of axial impairment, including both objective and subjective assessment of gait, but not with cognitive function. This study must be considered as just the opening salvo, which will have to be replicated by an independent group of investigators. It will be critical to include additional comparison groups, such as other parkinsonisms, Alzheimer disease, and nonparkinsonian patients with orthostatic hypotension.
A possible mechanistic substrate for these findings is provided by the observation that abnormal levels of angiogenic factors were detected exclusively in those patients with PD with coexisting orthostatic hypotension (a credible precursor to transient cerebral ischemia). The second is that BBB permeability (measured as the CSF/blood albumin ratio) correlates with levels of angiogenic factors in PD, but not in controls. The extent of WML did not differ between PD and controls, but correlated with CSF angiogenic factor levels in PD, and not in controls. Microbleeds in patients with PD were also associated with angiogenesis factor levels. The specificity of the findings is bolstered by 2 results: neurofilament light (a marker of neurodegeneration in general) but not tau (an indicator of Alzheimerrelated, cortical degeneration) correlated with CSF angiogenesis factors. Neurofilament protein (NFL) also correlated with the extent of WML in PD.
A surprising finding is just how specific these angiogenesis factor levels are: they do not correlate with amyloid levels in CSF or plaque density on histology, nor do they relate to tau levels in CSF or neurofibrillary tangle load on neuropathology.
What drives angiogenesis in PD? The authors provide a credible clue by examining, among other proinflammatory factors, the peptide MCP-1, which covaries with angiogenic factors in PD, but not in controls. These results have both immediate practical and long-term pathogenic implications.
It is possible to propose a mechanistic sequence. A proinflammatory stimulus initiates a cascade that promotes angiogenesis. The subsequent increase in BBB permeability leads to neurodegeneration andthrough the same or a different mechanism-to poor control of orthostatic blood pressure. The transient cerebral ischemia thus produced leads to WML, which results in impaired axial motor control, prominently affecting gait. Increased CSF NFL mirrors this development. The findings reported here suggest that this process affects only a subset of patients with PD, and occurs early, since there is no correlation with duration of disease. The identification of this subset-possibly by its association with orthostatic hypotension and WML-has implications for immediate action (since Food and Drug Administration-approved treatments exist) 8 as well as for future therapeutic developments.
From the point of view of pathogenesis, the study raises the question of what triggers the inflammation that drives the process. There is no shortage of answers. For example, we have speculated that Epstein-Barr virus may be involved 9 and that the appendix may be a site where the inflammatory process develops, 10 but other sound hypotheses have also been proposed. 11 
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